跳至主要内容
临床试验/JPRN-C000000319
JPRN-C000000319已完成4 期

The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension - J-ELA

J-ELAN study group0 个研究点目标入组 300 人开始时间: 2006年2月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
300

研究概览

简要总结

nder the similar reduction of blood pressure, losartan is likely effective in protecting the progression of atherosclerosis of the carotid artery compared to amlodipine. Losartan may improve LV diastolic function, and amlodipine may attenuate LV hypertrophy; however this study cannot make consecutive remarks about the superiority of either treatment regimen in the effects on cardiac function and geometry.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • History of a life-threatening adverse event induced by ARB or CCB •Pregnant woman •Serious liver dysfunction (aspartate aminotransferase or alanine aminotransferase more than 10 times of normal upper limit) •Serum creatinine > 1.8 mg/dl, known bilateral renal artery stenosis, single kidney, renal sclerosis •Secondary hypertension, malignant hypertension, hypertensive encephalopathy •Cardiovascular or cerebrovascular accidents within the last 6 months •Patients with angina pectoris who need CCB or beta-blocker •Significant aortic stenosis (peak transaortic valve pressure gradient > 20 mmHg) •Important aortic or mitral regurgitation in the investigators opinion •Patients with other diseases which affect the serum levels of carboxy-terminal telopeptide of collagen type I (CITP) and carboxy-terminal of procollagen type III (PIIIP) •Prescription of ACEI or ARB within 5 months •Prescription of beta-blocker or CCB within 4 weeks

研究者

发起方
J-ELAN study group

相似试验